Literature DB >> 35377927

Remimazolam: The Next Evolutionary Step for Sedative-Hypnotics.

Kyle J Kramer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35377927      PMCID： PMC8985456          DOI： 10.2344/anpr-69-01-07

Source DB:  PubMed          Journal:  Anesth Prog        ISSN： 0003-3006


× No keyword cloud information.
  4 in total

1.  A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokinetics.

Authors:  Laurie J Antonik; D Ronald Goldwater; Gavin J Kilpatrick; Gary S Tilbrook; Keith M Borkett
Journal:  Anesth Analg       Date:  2011-12-20       Impact factor: 5.108

2.  A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy.

Authors:  Douglas K Rex; Raj Bhandari; Taddese Desta; Michael P DeMicco; Cynthia Schaeffer; Kyle Etzkorn; Charles F Barish; Ronald Pruitt; Brooks D Cash; Daniel Quirk; Felix Tiongco; Shelby Sullivan; David Bernstein
Journal:  Gastrointest Endosc       Date:  2018-04-30       Impact factor: 9.427

Review 3.  Remimazolam for anaesthesia or sedation.

Authors:  J Robert Sneyd; Ann E Rigby-Jones
Journal:  Curr Opin Anaesthesiol       Date:  2020-08       Impact factor: 2.706

Review 4.  Remimazolam: Non-Clinical and Clinical Profile of a New Sedative/Anesthetic Agent.

Authors:  Gavin J Kilpatrick
Journal:  Front Pharmacol       Date:  2021-07-20       Impact factor: 5.810
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.